In this trial, antiplatelet therapy met the prespecified criterion for futility in critically ill patients based on very similar outcomes for organ support–free days compared with control.
The Randomised, Embedded, Multifactorial Adaptive Platform (REMAP-CAP) trial is the largest randomized clinical trial in critically ill patients with COVID-19 to report the effects of lopinavir-ritonavir, hydroxychloroquine and combination therapy of lopinavir-ritonavir and hydroxychloroquine compared with no antiviral therapy. We found that, among critically ill patients with COVID-19, lopinavirritonavir, hydroxychloroquine and combination therapy reduced organ support-free days and survival compared to no COVID-19 antiviral therapy.
BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of other immune modulating agents is unclear. METHODS We evaluated four immunomodulatory…
METHODS We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit…
OBJECTIVE To determine whether hydrocortisone improves outcome for patients with severe COVID-19. DESIGN, SETTING, AND PARTICIPANTS An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example,…
Accessibility
Cookies
Data protection
Help using our website
Terms and conditions
Europe University Medical Center, Utrecht Heidelberglaan 100 3584 CX, The Netherlands
Email: EU.remapcap@umcutrecht.nl
Tel: +31 88 75 551 96
REMAP-CAP ClinicalTrials.gov registration NCT02735707
REMAP-CAP EU Clinical Trials Register EudraCT number: 2015-002340-14
UMC Utrecht is the Sponsor for the trial in Europe and some countries outside Europe.
Sponsor is a consortium member in the project “Rapid European COVID-19 Emergency Research Response (RECOVER)” funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003589.
Inseparable to the design of this trial, platform conclusions are generated through frequent adaptive analyses as data accrues. To date, REMAP-CAP has contributed to the knowledge about the best treatment of COVID-19 with several results:
ACE2 RAS DOMAIN (27 Feb 2022)
Antiplatelet DOMAIN (23 Jun 2021)
CORTICOSTEROID DOMAIN
COVID-19 IMMUNE MODULATION DOMAIN
COVID-19 ANTI-COAGULATION DOMAIN
COVID-19 IMMUNOGLOBULIN DOMAIN
COVID-19 ANTIVIRAL DOMAIN
